of these sites now demonstrate earlier integration of supportive care within cancer through implementation of ESC -some have shown very significant increases in early referrals. In some sites, data points to an impact on reducing emergency admissions. Conclusions NHS England (NHSE) continues to build the case that ESC delivers improved value -reduced healthcare costs, improved QoL and optimises treatment decision making. Data collection is ongoing nationally and will inform national cancer policy and NHSE strategy. Formal research evaluation of ESC is expected begin in early 2018. Enhanced Supportive Care (ESC) is a new UK initiative that integrates supportive care within oncology. At its heart is better access to expertise in managing the adverse effects of cancer and cancer treatments to enhance the patient experience and reduce the need for hospital admission.
The Serious Illness Care Programme is a complex intervention developed in the US to improve communication between clinicians and patients with serious illness. In collaboration with Aridane Labs the programme has been developed for use within the UK, with pilot implementation funded by NHS England. Within the programme, clinicians are trained in use of a Serious Illness Conversation Guide (the guide), to structure conversations with patients/families. A feasibility of the UK programme is underway, within one North West cancer centre. Aim To present interim results from the feasibility study Methods Data on the use and experience of the UK programme, from the perspective of clinicians and patients Quantitative Data: Questionnaires: Clinicians -pre/post training:
. attitudes to care of the dying;
. acceptability of serious illness care programme
Patients -pre/post serious illness conversation:
. Enhanced Supportive Care (ESC) is a new UK initiative that integrates supportive care within oncology. At its heart is better access to expertise in managing the adverse effects of cancer and cancer treatments to enhance the patient experience and reduce the need for hospital admission.
ESC is award winning and has been recognised nationally by NHS England.
The aim of this audit was to measure the impact of ESC using the Integrated Palliative Care Outcome Scale (IPOS). This is a validated tool that can be used in clinical audit, research and training to measure symptom burden. Method 47 patients referred into the supportive care service, were randomly selected to complete the IPOS tool within 3 areas (inpatients, outpatients and trials unit) during May to October 2016. For all areas a baseline IPOS was completed prior to the initial assessment by supportive care. Subsequent IPOS were completed approximately 3 days later for inpatients. Outpatients and trial patients were reviewed at various time points depending on the timing of their follow up appointments. Outpatients had an average follow up of 41 days. Trial patients had an average follow up of 15 days. Results The overall IPOS score is the sum of the score of each of the 17 questions and can range from 0-68. A reduction in the IPOS score demonstrates an improvement in physical and psychological patient symptom burden. 16 inpatients completed the IPOS and demonstrated a 50% improvement in overall mean symptom score. 5 experimental cancer medicine patients completed the IPOS and demonstrated a 49% improvement in overall mean score. 26 oncology outpatients completed the IPOS and demonstrated a 2.5% deterioration in overall mean score, demonstrating a possible correlation between frequency of supportive care review and symptom burden. 
